Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Gastrointestinal 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 94Leukemia 18Leukemia, Myeloid, Chronic-Phase 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Blast Crisis 8Myeloproliferative Disorders 4Leukemia, Myeloid 4Bone Marrow Diseases 4Recurrence 3Philadelphia Chromosome 3Leukemia, Myeloid, Accelerated Phase 3Hematologic Diseases 3Bronchiolitis Obliterans Syndrome 3Hematologic Neoplasms 2Piebaldism 1Neoplastic Processes 1Neoplasms by Histologic Type 1Neoplasms 1Neoplasm, Residual 1Mastocytosis, Systemic 1Leukemia, Myeloid, Acute 1Hypereosinophilic Syndrome 1Gastrointestinal Stromal Tumors 1

Interventions

masitinib 2nilotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Piebaldism × nilotinib × Myeloid × Clear all
NCT01735955 2024-02-08

Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study

Novartis

Phase 4 Completed
57 enrolled 8 charts
GastrointestinalLymphoidMyeloidOther hematologic neoplasmSarcoma

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Piebaldism, Gastrointestinal Stromal Tumors, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡